Parkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

1. Identifying potential repurposable medications for Parkinson's disease through Mendelian randomization analysis.Scientific reports · 2024
   Pooled it
2. Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights.Current neurovascular research · 2026
   Review
3. Neurocognitive Psychiatric and Neuropsychological Alterations in Parkinson's Disease: A Basic and Clinical Approach.Brain sciences · 2023
   Review
4. Translational molecular imaging and drug development in Parkinson's disease.Molecular neurodegeneration · 2023
   Review
5. The protective impact of growth hormone against rotenone-induced apoptotic cell death via acting on endoplasmic reticulum stress and autophagy axis.Turkish journal of biology = Turk biyoloji dergisi · 2023
   Article
6. High-frequency rTMS improves quality of life and depressive symptoms in Parkinson's disease: A case report.Heliyon · 2022
   Article
7. Non-Oral Drug Delivery in Parkinson's Disease: Current Applications and Future.Turkish journal of pharmaceutical sciences · 2022
   Article
8. Long-Term Persistence and Monotherapy with Device-Aided Therapies: A Retrospective Analysis of an Israeli Cohort of Patients with Advanced Parkinson's Disease.Advances in therapy · 2022
   Article
9. Drug reprofiling history and potential therapies against Parkinson's disease.Frontiers in pharmacology · 2022
   Review
10. Intraperitoneal Administration of Forskolin Reverses Motor Symptoms and Loss of Midbrain Dopamine Neurons in PINK1 Knockout Rats.Journal of Parkinson's disease · 2022
    Article
11. Perceived exercise habits of individuals with Parkinson's disease living in the community.Clinical parkinsonism & related disorders · 2022
    Article
12. Current Therapies in Clinical Trials of Parkinson's Disease: A 2021 Update.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
13. Effects of bilateral subthalamic nucleus deep brain stimulation on motor symptoms in Parkinson's disease: a retrospective cohort study.Neural regeneration research · 2021
    Article
14. Blood Flow and Glucose Metabolism Dissociation in the Putamen Is Predictive of Levodopa Induced Dyskinesia in Parkinson's Disease Patients.Frontiers in neurology · 2019
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract